These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32237123)

  • 41. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
    Garinis GA; Gorgoulis VG; Mariatos G; Zacharatos P; Kotsinas A; Liloglou T; Foukas P; Kanavaros P; Kastrinakis NG; Vassilakopoulos T; Vogiatzi T; Field JK; Kittas C
    J Pathol; 2001 Jan; 193(1):55-65. PubMed ID: 11169516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
    Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
    J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.
    Lu Y; Wang Y; Zhang M; Liu L; Li F; Zhang J; Ye M; Zhao H; Zhao J; Yan B; Yang A; Zhang R; Li X; Ren X
    Oncotarget; 2016 Apr; 7(17):23594-607. PubMed ID: 26988752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
    Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
    Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
    Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
    J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression.
    Ji L; Fang B; Yen N; Fong K; Minna JD; Roth JA
    Cancer Res; 1999 Jul; 59(14):3333-9. PubMed ID: 10416589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TRIM47 overexpression is a poor prognostic factor and contributes to carcinogenesis in non-small cell lung carcinoma.
    Han Y; Tian H; Chen P; Lin Q
    Oncotarget; 2017 Apr; 8(14):22730-22740. PubMed ID: 28186994
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effects of ectogenous FHIT gene on reversing malignant phenotype of human lung adenocarcinoma cells A549].
    Wang Y; Zhuo Q; Qin Y; Yuan S; Sun Z; Wang Y; Chen X; Sun Z; Song Y; Yang Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun; 19(3):225-9. PubMed ID: 12048684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative assessment of the diagnostic role of FHIT promoter methylation in non-small cell lung cancer.
    Geng X; Pu W; Tan Y; Lu Z; Wang A; Tan L; Chen S; Guo S; Wang J; Chen X
    Oncotarget; 2017 Jan; 8(4):6845-6856. PubMed ID: 28036263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The force of HER2 - A druggable target in NSCLC?
    Jebbink M; de Langen AJ; Boelens MC; Monkhorst K; Smit EF
    Cancer Treat Rev; 2020 Jun; 86():101996. PubMed ID: 32135383
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trastuzumab in the treatment of non-small cell lung cancer.
    Azzoli CG; Krug LM; Miller VA; Kris MG; Mass R
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):59-65. PubMed ID: 11894015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
    Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Loss of exons of FHIT gene and FHIT protein expression in Yunnan tin miners with lung cancer].
    Ruan YH; Gao Q; Zhang L; Hua HR; Cheng JL; Jin KW
    Ai Zheng; 2007 Jun; 26(6):607-12. PubMed ID: 17562266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells.
    Wu R; Connolly DC; Dunn RL; Cho KR
    J Natl Cancer Inst; 2000 Feb; 92(4):338-44. PubMed ID: 10675384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.